These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29106609)

  • 1. First Chimeric Antigen Receptor T-Cell Therapy Approved.
    Brower V
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29106609
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor (CAR) T-Cell Therapy.
    Pagel JM; West HJ
    JAMA Oncol; 2017 Nov; 3(11):1595. PubMed ID: 28880983
    [No Abstract]   [Full Text] [Related]  

  • 4. The market for chimeric antigen receptor T cell therapies.
    Yip A; Webster RM
    Nat Rev Drug Discov; 2018 Mar; 17(3):161-162. PubMed ID: 29375140
    [No Abstract]   [Full Text] [Related]  

  • 5. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T-cell therapy for solid tumours.
    The Lancet Oncology
    Lancet Oncol; 2021 Jul; 22(7):893. PubMed ID: 34197740
    [No Abstract]   [Full Text] [Related]  

  • 7. Advances in off-the-shelf CAR T-cell therapy.
    Benjamin R
    Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953
    [No Abstract]   [Full Text] [Related]  

  • 8. Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy.
    Hardaway JC; Prince E; Arepally A; Katz SC
    J Vasc Interv Radiol; 2018 Jul; 29(7):1017-1021.e1. PubMed ID: 29935783
    [No Abstract]   [Full Text] [Related]  

  • 9. CAR T-cell Resistance to Oncogenic Transformation.
    Ruella M; June CH
    Blood Cancer Discov; 2024 Jul; 5(4):229-233. PubMed ID: 38713827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuning the performance of CAR T cell immunotherapies.
    Richardson NH; Luttrell JB; Bryant JS; Chamberlain D; Khawaja S; Neeli I; Radic M
    BMC Biotechnol; 2019 Nov; 19(1):84. PubMed ID: 31783836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cryopreservation on chimeric antigen receptor T cell functions.
    Xu H; Cao W; Huang L; Xiao M; Cao Y; Zhao L; Wang N; Zhou J
    Cryobiology; 2018 Aug; 83():40-47. PubMed ID: 29908946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T-cells for relapsed B-cell ALL in adults.
    Gilbert JA
    Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer therapy returns to original target: HIV.
    Cohen J
    Science; 2019 Aug; 365(6453):530. PubMed ID: 31395764
    [No Abstract]   [Full Text] [Related]  

  • 14. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards 'off-the-shelf' genetically modified T cells: prolonging functional engraftment in mice by CD8 veto T cells.
    Or-Geva N; Gidron-Budovsky R; Radomir L; Edelstein Y; Singh AK; Sidlik-Muskatel R; Ophir E; Bachar-Lustig E; Reisner Y
    Leukemia; 2018 Apr; 32(4):1039-1041. PubMed ID: 29151584
    [No Abstract]   [Full Text] [Related]  

  • 16. Engineering a solution for allogeneic CAR-T rejection.
    Amini L; Peter L; Schmueck-Henneresse M
    Mol Ther; 2024 Oct; 32(10):3204-3206. PubMed ID: 39265578
    [No Abstract]   [Full Text] [Related]  

  • 17. Epigenetic challenges on the horizon of chimeric antigen receptor-T.
    Benincasa G; Strozziero MG; Di Pastena MA; Criscuolo C; Cetani G; Trama U; Napoli C
    Cytotherapy; 2024 May; 26(5):411-412. PubMed ID: 38466261
    [No Abstract]   [Full Text] [Related]  

  • 18. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
    Jindal V; Arora E; Gupta S
    Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR T-cells for relapsed B-cell ALL in children and young adults.
    Stirrups R
    Lancet Oncol; 2018 Mar; 19(3):e144. PubMed ID: 29429913
    [No Abstract]   [Full Text] [Related]  

  • 20. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.